Immunocore Holdings plc (NASDAQ:IMCR) Stock Holdings Decreased by Two Sigma Investments LP

Two Sigma Investments LP cut its holdings in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 34.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 390,800 shares of the company's stock after selling 206,342 shares during the quarter. Two Sigma Investments LP owned approximately 0.78% of Immunocore worth $11,529,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its stake in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after buying an additional 960 shares in the last quarter. NEOS Investment Management LLC raised its holdings in shares of Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares during the last quarter. Tema Etfs LLC purchased a new stake in shares of Immunocore in the fourth quarter valued at $330,000. Virtus ETF Advisers LLC boosted its stake in shares of Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after acquiring an additional 3,238 shares during the last quarter. Finally, XTX Topco Ltd boosted its stake in shares of Immunocore by 22.2% during the fourth quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock valued at $557,000 after acquiring an additional 3,437 shares during the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Trading Down 1.7%

Immunocore stock traded down $0.55 during trading on Wednesday, reaching $31.49. The company had a trading volume of 1,041,710 shares, compared to its average volume of 392,866. Immunocore Holdings plc has a 12-month low of $23.15 and a 12-month high of $49.05. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The stock's 50 day moving average price is $29.09 and its two-hundred day moving average price is $29.97. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -33.15 and a beta of 0.75.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business's quarterly revenue was up 33.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.49) EPS. As a group, equities analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on IMCR shares. Needham & Company LLC reissued a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Oppenheimer upped their price objective on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Morgan Stanley restated an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a report on Tuesday. They issued a "buy" rating and a $65.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Immunocore presently has a consensus rating of "Moderate Buy" and a consensus target price of $58.89.

Insider Transactions at Immunocore

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the acquisition, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.40% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.